Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Nexvet Biopharma plc | d189064dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
May 12, 2016
Date of report (Date of earliest event reported)
Nexvet Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
| Ireland | 001-36828 | 98-1205017 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98, Ireland
(Address of principal executive offices, including zip code)
+353 5793 24522
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On May 12, 2016, Nexvet Biopharma public limited company (the “Company”) reported its financial results for the third quarter of fiscal year 2016 (the quarterly period ended March 31, 2016). The Company’s earnings release for this period is furnished herewith as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit |
Description | |
| 99.1 | Earnings release dated May 12, 2016 announcing the Company’s financial results for the third quarter of fiscal year 2016. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Nexvet Biopharma public limited company | ||
| By: | /s/ Mark Heffernan, Ph.D. | |
| Name: | Mark Heffernan | |
| Its: | Chief Executive Officer | |
Date: May 12, 2016